Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Muscular Dystrophy News4h
Sarepta to develop Arrowhead’s muscular dystrophy treatments
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Zacks Small Cap Research on MSN5h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
STAT6h
Sanofi pours $1 billion into China for insulin plant
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Le Lézard8h
BioVigil welcomes healthcare executive Erik Axter as Chief Executive Officer
BioVigil, the leader in electronic hand hygiene technology solutions for healthcare facilities, announces that its Board of Managers has appointed Erik Axter as its new Chief Executive Officer, ...
Arrowhead requests regulatory clearance to initiate ARO-ALK7 trial
Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second ...